Dose Proportionality of TFV-DP After a Single Dose of GS-7340 in Women

Dose Proportionality of TFV-DP in Mucosal Tissue, and Endogenous Nucleotide Quantification, After a Single Dose of GS-7340 in Women

Purpose:

The purpose of this study is to characterize the dose-proportionality in the distribution of tenofovir alafenamide (TAF) and tenofovir (TFV) in plasma and mucosal tissues, and TFV-diphosphate (TFV-DP) in peripheral blood mononuclear cells (PBMCs) and mucosal tissues of healthy female subjects following a single oral dose of GS-7430 at 5mg, 10mg, and 25mg.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: GS-7340

Detailed Description

Participants:

This study will consist of approximately 24 premenopausal healthy volunteer women between 18-49 years of age with an intact cervix, uterus, and gastrointestinal tract. Women will be enrolled in the study within 42 days of screening depending on the timing of their menstrual cycle in comparison to the screening visit, and then will be on study for 14 days, with follow-up 1-14 days after the end of study sampling. All study visits will be conducted in the North Carolina Translational and Clinical Sciences (NCTraCS) Clinical Translational Research Center (CTRC) at the University of North Carolina at Chapel Hill.

Procedures (methods):This is a Phase 1, single center, open-label, dose-ranging pharmacokinetic study of TFV and TFV-DP mucosal tissue concentrations measured after a single dose of GS-7340. Each arm is divided into three dosing groups: 5, 10, or 25mg. Participants will take a single dose of study drug within 7-14 days following the end of the subjects' menstrual period. Participants will be sequentially assigned to one of the three TAF doses and four biopsy schedules. Two women from each of the dosing groups will be assigned to one of four biopsy schedules for a total of 8 women per dosing group. Samples of blood plasma, cervicovaginal fluid (CVF), cervical tissue, vaginal tissue, and rectal tissue will be collected from participants at varying time points over the 14 days post-dose. Subjects will return to clinic within 14 days after the last sampling to complete a follow-up safety visit.

• Study Type: Interventional
• Enrollment (Actual): 24
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27599
      • University of North Carolina at Chapel Hill

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 49 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

Description

Inclusion Criteria

1. Healthy pre-menopausal female subjects between the ages of 18 and 49 years, inclusive on the date of screening, with an intact gastrointestinal tract, uterus, and cervix.
2. All subjects must have an estimated calculated creatinine clearance (eCcr) of at least 80 mL/min
3. All subjects must have negative pregnancy tests, and be using an acceptable form of birth control
4. Body Mass Index (BMI) of approximately 18 to 34 kg/m²; and a total body weight > 45 kg (99 lbs).
5. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial.
6. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures.
7. Subject must have documentation of a normal pap smear within 36 months of the screening visit, no procedures for abnormal cervical/vaginal pathology in the last six months, at least one prior gynecological visit as part of subject's routine medical history.
8. Subject must be willing to abstain from sexual intercourse, douching, and all intravaginal and intrarectal objects and products for at least 72 hours prior to Day 1 until study completion.
9. Subject must be HIV-1 and Hepatitis B surface antigen negative
10. Subject must not be actively involved in the conception process.
11. Subject must be able to swallow pills and have no allergies to any component of the study products

Exclusion Criteria

1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including documented drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
2. Subjects with a history of hysterectomy
3. Subjects who are pregnant, possibly pregnant or lactating
4. Subjects with a presence of vaginal discharge or genital bleeding at screening
5. History of febrile illness within five days prior to first dose.
6. Any condition possibly affecting drug absorption (eg, gastrectomy).
7. A positive urine drug screen.
8. A positive result for HIV, Hepatitis B or C
9. An untreated-positive test for syphilis, gonorrhea, Chlamydia, or trichomonas at screening, or symptomatic bacterial vaginosis.
10. Any laboratory chemistry or hematology result Grade 2 or greater according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) Laboratory Grading Tables
11. Treatment with an investigational drug within 4 months preceding the first dose of trial medication.
12. History of regular alcohol consumption exceeding study limits
13. Participation in a clinical trial involving vaginal or rectal biopsies within 6 months preceding the first dose of trial medication.
14. Use of prescription or nonprescription drugs, vitamins, and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of trial medication and unable to avoid use during the study period until after the last sample is collected.
15. Blood donation of approximately 1 pint (500 mL) within 56 days prior to dosing.
16. History of sensitivity to heparin or heparin-induced thrombocytopenia.
17. Allergy to lidocaine or Monsel's solution.
18. Allergy to latex.
19. Abnormal pap smear in the past 36 months
20. Any degree of ectopy or abnormality evident during the pelvic exam at screening.
21. Any condition which, in the opinion of the investigator, is likely to interfere with follow-up or ability to take the study medication appropriately.
22. Unwilling or unable to comply with the dietary and concomitant drug restrictions in regard to study drug administration as outlined in the study procedures and prohibited medications sections.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 1. GS-7340 25mg; The first 8 women on study will be assigned to take a single dose of 25mg TAF (1 tablet) orally.	Drug: GS-7340; Medication is supplied in 10 or 25mg tablets, so subjects will receive either 1/2 or one tablet in a single dose.; Other Names: TAF; Tenofovir Alafenamide
Experimental: 2. GS-7340 10mg; The 2nd group of 8 women will be sequentially assigned to take a single dose of 10mg TAF (1 tablet) orally.	Drug: GS-7340; Medication is supplied in 10 or 25mg tablets, so subjects will receive either 1/2 or one tablet in a single dose.; Other Names: TAF; Tenofovir Alafenamide
Experimental: 3. GS-7340 5mg; The final 8 women on study will be sequentially assigned to take a single dose of 5mg TAF (1/2 tablet) orally.	Drug: GS-7340; Medication is supplied in 10 or 25mg tablets, so subjects will receive either 1/2 or one tablet in a single dose.; Other Names: TAF; Tenofovir Alafenamide

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Plasma Dose-Proportionality	To characterize the dose-proportionality in the distribution of TAF and TFV in the plasma of healthy female subjects following a single oral dose of GS-7340 at 5mg, 10mg, and 25mg. This will be used to develop a predictive pharmacokinetic model for TAF which will allow for TFVdp exposure predictions given a specific dose and dosing interval.	Pre-dose and 1, 3, 6, 12, 24 hours, and 3, 7, 10, and 14 days following single dose
Tissue Dose-Proportionality	To characterize the dose-proportionality in the distribution of TAF and TFV in mucosal tissues, and TFV-DP in mucosal tissues of healthy female subjects following a single oral dose of GS-7340 at 5mg, 10mg, and 25mg. This will be used to develop a predictive pharmacokinetic model for TAF which will allow for TFVdp exposure predictions given a specific dose and dosing interval.	At 3, 6, 12 and 24 hours and 3, 7, 10 and 14 days following single dose
PBMC Dose-Proportionality	To characterize the dose-proportionality in the distribution of TFV-DP in PBMCs of healthy female subjects following a single oral dose of GS-7340 at 5mg, 10mg, and 25mg. This will be used to develop a predictive pharmacokinetic model for TAF which will allow for TFVdp exposure predictions given a specific dose and dosing interval.	Pre-dose and 3, 6, 12, 24 hours and 3, 7, 10, and 14 days following single dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Intra-subject variability in intracellular deoxyadenosine triphosphate (dATP) in peripheral blood	To determine intra-subject variability in intracellular dATP in PBMCs and ratios of TFVdp:dATP.	Pre-dose and 3, 6, 12, 24 hours and 3, 7, 10, and 14 days following single dose
Inter-subject variability in intracellular deoxyadenosine triphosphate (dATP) in peripheral blood	To determine inter-subject variability in intracellular dATP in PBMCs and ratios of TFVdp:dATP.	Pre-dose and 3, 6, 12, 24 hours and 3, 7, 10, and 14 days following single dose
Intra-subject variability in intracellular deoxyadenosine triphosphate (dATP) in mucosal tissues	To determine intra-subject variability in intracellular dATP in cervical, vaginal, and rectal tissues and ratios of TFVdp:dATP.	At 3, 6, 12 and 24 hours and 3, 7, 10 and 14 days following single dose
Inter-subject variability in intracellular deoxyadenosine triphosphate (dATP) in mucosal tissues	To determine inter-subject variability in intracellular dATP in cervical, vaginal, and rectal tissues and ratios of TFVdp:dATP.	At 3, 6, 12 and 24 hours and 3, 7, 10 and 14 days following single dose

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cervicovaginal Fluid (CVF) Concentration	To determine if TFV and TAF concentration in CVF changes in proportion to TFV, TAF, and TFV-DP concentration in cervical and vaginal tissue	At 1, 3, 6, 12, 24 hours and 3, 7, 10, and 14 days following single dose.

Collaborators and Investigators

• Sponsor: University of North Carolina, Chapel Hill
• Collaborators: Gilead Sciences
• Investigators: Principal Investigator: Angela DM Kashuba, PharmD, UNC Chapel Hill

Publications and helpful links

General Publications

• Cottrell ML, Garrett KL, Prince HMA, Sykes C, Schauer A, Emerson CW, Peery A, Rooney JF, McCallister S, Gay C, Kashuba ADM. Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues. J Antimicrob Chemother. 2017 Jun 1;72(6):1731-1740. doi: 10.1093/jac/dkx064.

Study record dates

Study Major Dates

• Study Start: March 1, 2015
• Primary Completion (Actual): October 1, 2015
• Study Completion (Actual): November 1, 2016

Study Registration Dates

• First Submitted: January 14, 2015
• First Submitted That Met QC Criteria: February 2, 2015
• First Posted (Estimate): February 6, 2015

Study Record Updates

• Last Update Posted (Estimate): November 30, 2016
• Last Update Submitted That Met QC Criteria: November 29, 2016
• Last Verified: November 1, 2016

More Information

Terms related to this study

• Keywords: Participants; HIV-1 negative
• Additional Relevant MeSH Terms: Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Reverse Transcriptase Inhibitors; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Anti-HIV Agents; Anti-Retroviral Agents; Tenofovir
• Other Study ID Numbers: 14-2797